KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Total Liabilities: 2009-2025

Historic Total Liabilities for Halozyme Therapeutics (HALO) over the last 17 years, with Sep 2025 value amounting to $1.7 billion.

  • Halozyme Therapeutics' Total Liabilities rose 3.12% to $1.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 billion, marking a year-over-year increase of 3.12%. This contributed to the annual value of $1.7 billion for FY2024, which is 3.04% up from last year.
  • Per Halozyme Therapeutics' latest filing, its Total Liabilities stood at $1.7 billion for Q3 2025, which was down 0.22% from $1.7 billion recorded in Q2 2025.
  • Halozyme Therapeutics' 5-year Total Liabilities high stood at $1.8 billion for Q3 2022, and its period low was $899.0 million during Q1 2021.
  • Over the past 3 years, Halozyme Therapeutics' median Total Liabilities value was $1.7 billion (recorded in 2024), while the average stood at $1.7 billion.
  • Its Total Liabilities has fluctuated over the past 5 years, first surged by 115.01% in 2021, then decreased by 7.02% in 2023.
  • Quarterly analysis of 5 years shows Halozyme Therapeutics' Total Liabilities stood at $907.5 million in 2021, then spiked by 84.22% to $1.7 billion in 2022, then dropped by 1.33% to $1.6 billion in 2023, then rose by 3.04% to $1.7 billion in 2024, then climbed by 3.12% to $1.7 billion in 2025.
  • Its last three reported values are $1.7 billion in Q3 2025, $1.7 billion for Q2 2025, and $1.7 billion during Q1 2025.